Home Hot keywords

Search Modes

All

Search Results

AT-1501
AT-1501 (antiCD40L) is an antibody therapeutic with comprehensive and promising preclinical data. It blocks specific immune cell activation and protects ...
Aug 27, 2021AT-1501 (anti-CD40L) is an experimental therapy aiming to delay the onset of amyotrophic lateral sclerosis (ALS) and slow its progression.
Mar 26, 2020This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L.
Phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours ...
AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic ...
Oct 7, 2021AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing ...
A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults with ALS.
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ...
Images
Image result for AT-1501
Image result for AT-1501
Image result for AT-1501
Image result for AT-1501
Image result for AT-1501
Image result for AT-1501
Select an image to give feedback
Feedback
Amyotrophic Lateral Sclerosis · Intervention Type: Drug. Intervention Name: AT-1501. Description: AT-1501 monoclonal antibody targeting CD40L given as an IV ...

Page Navigation

google search trends